Volume 16, Issue 10 (October 2018)                   IJRM 2018, 16(10): 623-628 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hestiantoro A, Hasani R D K, Shadrina A, Situmorang H, Ilma N, Muharam R, et al . Body fat percentage is a better marker than body mass index for determining inflammation status in polycystic ovary syndrome. IJRM 2018; 16 (10) :623-628
URL: http://ijrm.ir/article-1-1265-en.html
Body fat percentage is a better marker than body mass index for determining inflammation status in polycystic ovary syndrome
Andon Hestiantoro * 1, Rachmat Dediat Kapnosa Hasani1 , Amalia Shadrina1 , Herbert Situmorang1 , Nurul Ilma1 , Raden Muharam1 , Kanadi Sumapraja1 , Budi Wiweko1
1- Department of Obstetrics and Gynecology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Abstract:   (3393 Views)
Background: Polycystic ovary syndrome (PCOS) is an endocrinopathic disorder most commonly experienced by women of reproductive age, and it is characterized by a low-grade chronic inflammatory condition. Excessive fat deposit has been long considered as an etiological factor in the pathogenesis of this inflammatory condition. Currently, body mass index (BMI) or percentage of body fat is used as a marker to assess the body fat composition of a person.
Objective: To determine whether BMI or body fat percentage (BFP) can be used as a better marker for measuring inflammation related to body fat accumulation in polycystic ovary syndrome patients.
Materials and Methods: This study took place at the Center for Reproductive Medicine, Yasmin Clinic, Cipto Mangunkusumo Hospital from January to December 2015. In this cross-sectional study, 32 reproductive age women with PCOS according to the Rotterdam criteria (2003) participated. Women with hyperandrogenism caused by non-classic congenital adrenal hyperplasia, pregnant and lactating women, etc., were excluded. Some variables such as BMI, clinical hyperandrogenism sign, BFP, and inflammatory markers were assessed and statistically analyzed.
Results: From a total of 32 subjects of the study, BFP had a significant positive correlation with procalcitonin levels (r=0.35; p=0.048), while BMI did not (r=0.27; p=0.131).
Conclusion: BFP can be used as a better marker for measuring inflammation related to body fat accumulation in PCOS subjects.
Keywords: Body fat, Body mass index, Inflammation, Polycystic ovary syndrome, Procalcitonin.
Full-Text [PDF 273 kb]   (776 Downloads) |   |   Full-Text (HTML)  (478 Views)  
Type of Study: Original Article |
References
1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13. [DOI:10.2147/CLEP.S37559]
2. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2008; 22: 261-274. [DOI:10.1016/j.bpobgyn.2007.07.009]
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236. [DOI:10.1056/NEJMra041536]
4. Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010; 26: 281-296. [DOI:10.3109/09513590903247873]
5. Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)-A novel theory for the development of Polycystic Ovarian Syndrome. Med Hypotheses 2012; 79: 104-112. [DOI:10.1016/j.mehy.2012.04.016]
6. Marino JS, Iler J, Dowling AR, Chua S, Bruning JC, Coppari R, et al. Adipocyte dysfunction in a mouse model of polycystic ovary syndrome (PCOS): evidence of adipocyte hypertrophy and tissue-specific inflammation. PLos One 2012; 7: 1-10. [DOI:10.1371/journal.pone.0048643]
7. Rojas J, Chavez M, Olivar L, Rojas M, Morillo J, Mefijas J, et al. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. Int J Reprod Med 2014; 2014: 719050. [DOI:10.1155/2014/719050]
8. Gonzalez F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77: 300-305. [DOI:10.1016/j.steroids.2011.12.003]
9. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014; 34: 263-273. [DOI:10.3343/alm.2014.34.4.263]
10. Göde F, Yücesoy FB, Akarsu S, Sağlam A, Orem A, Sharafkhanov K. Serum procalcitonin and proinflammatory markers in polycystic ovary syndrome. Gynecol Obstet Reprod Medi 2017; 23: 20-25.
11. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 323: 17-29. [DOI:10.1016/S0009-8981(02)00101-8]
12. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 2016; 106: 6-15. [DOI:10.1016/j.fertnstert.2016.05.003]
13. Rashad NM, El-Shal AS, Abelaziz AM. Association between inflammatory biomarker serum procalcitonin and obesity in women with polycystic ovary syndrome. J Reprod Immunol 2013; 97: 232-239. [DOI:10.1016/j.jri.2012.10.007]
14. Escobar-Morreale HF, San-Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007; 18: 266-272. [DOI:10.1016/j.tem.2007.07.003]
15. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014-6021. [DOI:10.1210/jc.2005-1002]
16. Nadia-Mudher AH, Haydar-Hashim AS. Procalcitonin as a mediator of chronic inflammation in obese women with PCOS. Med J Babyl 2010; 7: 505-510.
17. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review 1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13.
18. Oliveros E, Somers VK, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Prog Cardiovasc Dis 2014; 56: 426-433. [DOI:10.1016/j.pcad.2013.10.003]
19. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. Intl J Obstet Gynecol 2006; 113: 1148-1159.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb